2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

401 PRAME expression is correlated with molecular subtypes and treatment outcome in classic Hodgkin lymphoma

Shinya Rai, MD, PhD, Katsuyoshi Takata, MD, PhD2, Gerben Duns, PhD3, Aixiang Jiang, PhD4, Yifan Yin, PhD5, Manabu Fujisawa, MD, PhD6, Tomoko Miyata-Takata7, Adele Telenius, BSc, MPhil8, Barbara Meissner9, Merrill Boyle10, Hisae Nakamura11, Andrew Lytle, MD, PhD12, Pedro Farinha, MD, PhD13, Graham Slack14, Tomohiro Aoki, MD, PhD15, Kerry Savage, MD, MSc, BSc16, David Scott, MD17, Christian Steidl, MD18
1 BC Cancer, Vancouver, British Columbia, Canada, Faculty of Medicine, Kindai University, Sakai, Japan
2 Academic Assembly Faculty of Medicine, University of Toyama, Toyama, Japan, BC Cancer, Vancouver, British Columbia, Canada
3 BC Cancer, Vancouver, British Columbia, Canada
4 BC Cancer, Vancouver, British Columbia, Canada
5 BC Cancer, Vancouver, British Columbia, Canada
6 BC Cancer, Vancouver, British Columbia, Canada
7 BC Cancer, Vancouver, British Columbia, Canada
8 BC Cancer, Vancouver, British Columbia, Canada
9 BC Cancer, Vancouver, British Columbia, Canada
10 BC Cancer, Vancouver, British Columbia, Canada
11 BC Cancer, Vancouver, British Columbia, Canada
12 BC Cancer, Vancouver, British Columbia, Canada
13 BC Cancer, Vancouver, British Columbia, Canada, The University of British Columbia, Vancouver, Vancouver, British Columbia, Canada
14 BC Cancer, Vancouver, British Columbia, Canada
15 Princess Margaret Cancer Centre, Tronto, Ontario, Canada
16 BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, Vancouver, British Columbia, Canada
17 BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, Vancouver, British Columbia, Canada
18 BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, Vancouver, British Columbia, Canada

Introduction: Classic Hodgkin lymphoma (cHL) is characterized by malignant Hodgkin/Reed-Sternberg (HRS) cells orchestrating a highly organized tumor microenvironment (TME). While our recent multidimensional profiling identified four distinct molecular subtypes that are associated with specific composition and function of the TME (Aoki T et al, 2026), the role of HRS-cell tumor antigenicity in these ecosystems remains unexplored. Here, we focused on PRAME, a clinically actionable cancer-testis antigen that generates HLA-presented peptides recognizable by cytotoxic T cells, and explored whether PRAME-defined tumor antigenicity is associated with HRS-cell-intrinsic programs, TME biology, and prognostic stratification in cHL.

Methods: We performed PRAME immunohistochemistry in a BC Cancer cohort spanning major lymphoma entities, including diffuse large B-cell lymphoma (DLBCL, n=319), follicular lymphoma (FL, n=166), transformed FL (tFL, n=166), mantle cell lymphoma (MCL, n=180), and cHL (n=166). PRAME negativity was defined as the complete absence of tumor-cell staining. HRS cell PRAME status was integrated with multidimensional datasets as published (Aoki T et al, 2026; ‘LMD cohort’), including mutational status, GeoMx captured HRS cell transcriptional programs, and imaging mass cytometry resolved TME topographies. Prognostic significance was further assessed in a published dataset enriched for relapse/progression events (Steidl C et al, 2010; ‘NEJM cohort’) and a subset of E2496 trial patients with available tissue biopsies (Evens AM et al, 2013; ECOG cohort). Outcome correlations of PRAME expression were tested using multivariable Cox proportional hazards models adjusted for PRAME, EBV status by in situ hybridization, and International Prognostic Score (0–2 vs ≥3).

Results: cHL exhibited the highest frequency of PRAME positivity (69%) among all major lymphoma entities tested (DLBCL 32.6%, FL 7.8%, tFL 14.5%, MCL 7.8%). This finding contrasts with the lack of expression in non-neoplastic germinal centers and normal B cells, confirming aberrant tumor-associated PRAME expression in HRS cells. In the LMD cohort, all six tumors harboring 22q11/PRAME locus deletion lacked detectable PRAME expression, whereas 18 of 73 tumors without detectable locus deletion were also PRAME-negative (p<0.001). Thus, locus deletions only partially explain PRAME negativity, implicating alternative mechanisms like epigenetic silencing, as previously reported. When mapped onto the framework of genetic subtypes (HLGen), EBV-positive/PRAME-negative tumors were highly enriched in the CN913 subtype (~90%). In contrast, EBV-negative/PRAME-negative tumors were equally distributed across all four HLGen classes, providing a rationale for further EBV-stratified correlative analyses. In EBV-positive cHL, PRAME-negative HRS cells showed enrichment of multiple interferon-related transcriptional programs and associated with a suppressive TME rich in PD-L1+/CD163+/TIM-3+ macrophages and exhausted T cells. In contrast, EBV-negative/PRAME-negative HRS cells lacked these inflammatory signatures and were enriched for PI3K-AKT-mTOR survival signaling and suppressive NK-cell programs.

PRAME negativity was associated with significantly inferior overall survival (OS) in both the NEJM cohort (p=0.016; median follow-up 14.7 years) and the ECOG cohort (p<0.0001; median follow-up 5.3 years). This survival difference was most pronounced within the EBV-negative stratum. In multivariable Cox models, PRAME negativity remained a robust, independent predictor of inferior OS (NEJM cohort: HR 2.36, 95% CI 1.19–4.65, p=0.01; ECOG cohort: HR 9.25, 95% CI 4.15–20.59, p<0.001). To integrate antigen availability with presentation capacity, we jointly assessed PRAME and MHC class I status in the LMD cohort. Combined PRAME/MHC class I status stratified progression-free survival (PFS) (log-rank p=0.025), with 5-year PFS ranging from 89.5% in PRAME-positive/MHC class I–positive cases to 40.0% in double-negative cases.

Conclusion: In cHL, PRAME expression might be linked to distinct EBV-associated immune escape strategies within the TME. Absent PRAME expression is correlated with a more aggressive disease course, predominantly in the EBV-negative subgroup of patients. Our findings support PRAME expression as a practical biomarker associated with high-risk cHL biology and provide a rationale for future studies combining antigen-restoring strategies with PRAME-directed immunotherapy.

Shinya Rai, MD, PhD: Chugai Pharmaceutical, Genmab, AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Incyte Biosciences Japan, Janssen Pharmaceutical - Honoraria